GlassScriptPhysician profile
Thomas Di Julio
NPI 1396712188
$401.98
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.19 · 2020: $76.78 · 2021: $176 · 2022: $53.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $204.81 | 2020-2022 | |
| Biogen, INC. | $51.57 | 2019-2020 | |
| Sk Life Science, INC. | $33.92 | 2022 | |
| Amgen INC. | $30.60 | 2019 | |
| Allergan, INC. | $23.72 | 2020 | |
| Abbvie INC. | $16.55 | 2021 | |
| Kyowa Kirin, INC. | $14.39 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.14 | 2019 | |
| Genentech USA, INC. | $12.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Di Julio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.